Cognitive behavioural therapy for weight gain associated with antipsychotic drugs

Khazaal, Yasser; Fresard, Emmanuelle; Rabia, S.; Chatton, Anne; Rothen, Stéphane; Pomini, Valentino; Grasset, François; Borgeat, François; Zullino, Daniele

doi:10.1016/j.schres.2006.12.025

Cited by 72 publications

(70 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, as previously found in a population with psychotic disorder, the BMAC was also correlated to the BMI [16], highlighting the possible interest of the BMAC in this population in consideration that change in cognitions may enhance weight loss and lower BED [20]. Further studies documenting the scale's sensitivity to changes in body weight and eating behaviors are warranted.…”

Section: Discussionsupporting

confidence: 67%

See 1 more Smart Citation

A Measure of Dysfunctional Eating-Related Cognitions in People with Psychotic Disorders

et al. 2009

Self Cite

View full text Add to dashboard Cite

Obesity and binge eating disorder are common in individuals with psychotic disorders. Eating and weight-related cognitions are known to influence eating behaviors. The study was designed to assess the psychometric properties of the Mizes Anorectic Cognitions Questionnaire (MAC-R) in patients with psychotic disorders. Binge eating disorder (BED), body mass index (BMI), the MAC-R and the three factor eating questionnaire (TFEQ) were assessed in 125 patients with a diagnosis of schizophrenia or schizoaffective disorder. Whereas the MAC-R has not acceptable psychometric properties, a brief version of the MAC-R (BMAC) has good psychometrical properties and is correlated with TFEQ and BMI. Binge eating disorder is also correlated to the Rigid Weight Regulation and Fear of Weight Gain subscale. The BMAC is a useful brief measure to assess eating and weight related cognitions in people with psychotic disorders.

show abstract

Section: Discussionsupporting

confidence: 67%

“…The MAC-R was already used among people with psychotic disorders and it was furthermore found that a cognitive and behavioral treatment including interventions aiming to change these cognitions was effective in this population [20].…”

Section: Introductionmentioning

confidence: 99%

A Measure of Dysfunctional Eating-Related Cognitions in People with Psychotic Disorders

et al. 2009

Self Cite

View full text Add to dashboard Cite

show abstract

“…19,20 It would be desirable to consider mitigation treatments for those patients in whom weight gain can be predicted. Treatments for mitigation of weight gain, specifically during antipsychotic treatment, have been reported and include nonpharmacological interventions such as individualized education and support, 21,22 cognitive behavioral therapy, 22 structured dietary education, physical activity programs, 23 and inpatient psychoeducation. 3,24 Because OFC is approved for the short-term treatment of depressive episodes associated with bipolar I disorder in adults and for the short-term treatment of TRD (defined as major depressive disorder [MDD] in adults who do not respond to 2 separate trials of different antidepressants of adequate dose and duration in the current episode) in the United States, 18 this study explores early weight gain (EWG) as a predictor of subsequent substantial weight gain (SWG) in patients who have TRD and who are taking OFC.…”

mentioning

confidence: 99%

Early Weight Gain as a Predictor of Substantial Weight Gain With Olanzapine/Fluoxetine Combination

Degenhardt

Jamal²,

Tormey³

et al. 2011

Journal of Clinical Psychopharmacology

View full text Add to dashboard Cite

Weight gain during olanzapine/fluoxetine combination (OFC) therapy is very common. We examined early (at 2 weeks) weight gain as a predictor of later (at 26 weeks) substantial weight gain in patients with treatment-resistant depression during OFC pharmacotherapy. Data were analyzed from 2 studies (Study 1 and Study 2)-each with an acute, double-blind phase and an open-label phase-in patients who completed 26 weeks of open-label treatment (N = 306). Mean patient age was 46 years; the majority was female and white. Sensitivity, specificity, and positive and negative predictive values (PPV and NPV) were examined using early weight gain of 2 kg or more as a predictor of 10 kg or more substantial weight gain. Sensitivity (true positive rate) and specificity for Study 1 (n = 73) were 33% and 71%, respectively; PPV and NPV were 23% and 80%, respectively. Sensitivity and specificity for Study 2 (n = 233) were 52% and 70%, respectively; PPV and NPV were 31% and 85%, respectively. Overall, in the 2 trials analyzed, for patients who did not gain 2 kg or more (2.54 lb) in the first 2 weeks of OFC treatment, the observed frequency was 16.3% for gaining 10 kg or more at 26 weeks. Compared to those with early weight gain, patients without early weight gain were less likely to have substantial weight gain after OFC treatment. Additional research is needed to further explore the predictive power of early weight gain for subsequent substantial weight gain in patients with treatment-resistant depression treated with OFC.

show abstract

“…Some studies even demonstrated a relative advantage of behavioural techniques compared with diet or brief nutritional information [Harmatz and Lapuc, 1968;Khazaal et al 2007]. Of note are two large naturalistic studies of structured wellbeing programmes (targeting both physical and mental health with emphasis on healthy lifestyle promotion) which showed weight reduction or improvements in lifestyle habits [Smith et al 2007;Lindenmayer et al 2009].…”

Section: Description and Discussion Of Studiesmentioning

confidence: 99%

Interventions for the metabolic syndrome in schizophrenia: a review

Papanastasiou¹

2012

Therapeutic Advances in Endocrinology

View full text Add to dashboard Cite

Abstract:The metabolic syndrome (MetS) is an increasingly prevalent condition in people with schizophrenia. It remains highly prevalent in the general population in developed countries, but recently health promotion campaigns and greater awareness of the high associated mortality rates have resulted in improvements in the rates of cardiovascular risk factors. This is not the case for people with schizophrenia who continue to have more than twice the rates of MetS and significantly higher mortality rates than the general population. Various behavioural and pharmacological interventions have been used to improve conditions that are linked to MetS, mainly smoking and obesity. This review aims to provide an update of the latest knowledge about the behavioural, pharmacological and other interventions that might help to combat this life-threatening problem in people with schizophrenia.

show abstract

Cognitive behavioural therapy for weight gain associated with antipsychotic drugs

Cited by 72 publications

References 55 publications

A Measure of Dysfunctional Eating-Related Cognitions in People with Psychotic Disorders

A Measure of Dysfunctional Eating-Related Cognitions in People with Psychotic Disorders

Early Weight Gain as a Predictor of Substantial Weight Gain With Olanzapine/Fluoxetine Combination

Interventions for the metabolic syndrome in schizophrenia: a review

Contact Info

Product

Resources

About